文献速递炎症性肠病

抗TNF治疗诱导期早期检测抗药抗体可预测炎症性肠病治疗中断

Early detection of anti-drug antibodies during initiation of anti-tumour necrosis factor therapy predicts treatment discontinuation in inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2021-04-19

第2周抗体阳性率高达76%(ADA)和67%(IFX),且抗体浓度超过阈值者治疗中断时间显著缩短,抗体是唯一与治疗中断相关的因素。

要点

  • 药物耐受法可在诱导期早期检出高比例抗药抗体。
  • 第2周抗体浓度达阈值者治疗中断风险显著增高。
  • 早期抗体阳性是预测24个月内治疗失败的独立因素。

核心结论

  • 药物耐受法早期检测的抗TNF抗体阳性率高,其出现可预测后续治疗中断。

主要发现

  • 第2周阿达木单抗抗体阳性率为76%,英夫利西单抗抗体阳性率为67%。
  • 第2周ADA抗体≥2.0 µg/mL-eq者治疗中断时间显著短于无抗体者(6.0 vs 24个月,HR=18.51,95%CI 4.35-78.71,P<0.001)。
  • 第2周IFX抗体≥4.0 µg/mL-eq者治疗中断时间显著短于无抗体者(5.5 vs >24个月,HR=13.89,95%CI 4.08-47.31,P<0.001)。
  • ADA和IFX抗体预测24个月内治疗失败的敏感性分别为79%和62%,特异性和阳性预测值均为100%。
  • 多因素分析中,第2周ADA或IFX抗体是唯一与治疗中断相关的因素。

临床怎么用

  • 可考虑在抗TNF诱导期早期(第2周)用药物耐受法检测抗药抗体以识别高停药风险患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-drug antibodies develop mostly during the induction therapy with anti-tumour necrosis factor (TNF) drugs and can be revealed by means of a drug-tolerant assay. AIM: To investigate whether the early detection of anti-drug antibodies during the induction therapy was predictive of treatment discontinuation. METHODS: In a prospective study, consecutive patients with inflammatory bowel disease (IBD), who should start an anti-TNF, were enrolled and followed regularly during 24 months or less in case of non- or loss of response (LOR) or adverse events requiring treatment discontinuation. Anti-TNF levels and anti-drug antibodies were measured at week 2 for adalimumab (ADA) and weeks 2 and 6 for infliximab (IFX) using a drug-tolerant assay. RESULTS: One hundred and eight patients were enrolled (54 under ADA). At week 2, antibodies to ADA and to IFX were detected in 76% and 67% of patients. Time to treatment discontinuation was significantly shorter (P < 0.001) in patients with antibodies to ADA ≥2.0 µg/mL-eq (6.0 vs 24 months, HR = 18.51, 95% CI [4.35-78.71]) or with antibodies to IFX ≥4.0 µg/mL-eq (5.5 vs >24 months, HR = 13.89, 95% CI [4.08-47.31]) at week 2 compared to patients without positive antibodies. Antibodies to ADA and to IFX were predictive of treatment failure within 24 months with a sensitivity of 79% and 62%, and specificities and positive predictive values of 100%. In multivariate analysis, antibodies to ADA or to IFX at week 2 were the only factors associated with treatment discontinuation. CONCLUSIONS: The prevalence of antibodies to anti-TNF is high when detected early using a drug-tolerant assay, and their appearance predicts further treatment discontinuation.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Tournier Q, Paul S, Williet N, et al. Early detection of anti-drug antibodies during initiation of anti-tumour necrosis factor therapy predicts treatment discontinuation in inflammatory bowel disease. Aliment Pharmacol Ther. 2021. PMID: 33872404. doi:10.1111/apt.16333

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。